![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Preclinical antiviral drug combination studies utilizing novel orally bioavailable agents for chronic hepatitis B infection: AB-506, a next generation HBV capsid inhibitor, and AB-452, an HBV RNA destabilizer
|
|
|
full pdf slide presentation attached
Reported by Jules Levin
EASL - The International Liver Congress 2018,
April 11 -15, 2018, Paris, France
Rene Rijnbrand
Arbutus Biopharma Inc.
Download the PDF here
![0427181](../images%20/042718/042718-2/0427181.gif)
![HBV](../images%20/042718/042718-2/HBV.gif)
Source: Hepatitis B. WHO (2017) http://www.who.int/mediacentre/factsheets/fs204/en/
![0427183](../images%20/042718/042718-2/0427183.gif)
![0427184](../images%20/042718/042718-2/0427184.gif)
![0427185](../images%20/042718/042718-2/0427185.gif)
![0427186](../images%20/042718/042718-2/0427186.gif)
![0427187](../images%20/042718/042718-2/0427187.gif)
![0427188](../images%20/042718/042718-2/0427188.gif)
![0427189](../images%20/042718/042718-2/0427189.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|